- Home
- GMAB vs ZTO Comparison
GMAB vs ZTO Comparison
Compare GMAB & ZTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- ZTO
- Stock Information
- Founded
- GMAB 1999
- ZTO 2002
- Country
- GMAB Denmark
- ZTO China
- Employees
- GMAB N/A
- ZTO N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- ZTO Advertising
- Sector
- GMAB Health Care
- ZTO Consumer Discretionary
- Exchange
- GMAB Nasdaq
- ZTO Nasdaq
- Market Cap
- GMAB 17.4B
- ZTO 15.2B
- IPO Year
- GMAB N/A
- ZTO 2016
- Fundamental
- Price
- GMAB $30.42
- ZTO $18.98
- Analyst Decision
- GMAB Strong Buy
- ZTO Strong Buy
- Analyst Count
- GMAB 6
- ZTO 4
- Target Price
- GMAB $40.40
- ZTO $21.90
- AVG Volume (30 Days)
- GMAB 2.4M
- ZTO 1.2M
- Earning Date
- GMAB 11-06-2025
- ZTO 11-19-2025
- Dividend Yield
- GMAB N/A
- ZTO 3.17%
- EPS Growth
- GMAB 132.41
- ZTO N/A
- EPS
- GMAB 25.10
- ZTO 1.13
- Revenue
- GMAB $3,845,670,022.00
- ZTO $6,465,566,040.00
- Revenue This Year
- GMAB $24.92
- ZTO $11.99
- Revenue Next Year
- GMAB $15.97
- ZTO $12.30
- P/E Ratio
- GMAB $11.82
- ZTO $16.80
- Revenue Growth
- GMAB 29.57
- ZTO 14.70
- 52 Week Low
- GMAB $17.24
- ZTO $16.34
- 52 Week High
- GMAB $33.65
- ZTO $22.01
- Technical
- Relative Strength Index (RSI)
- GMAB 56.40
- ZTO 49.47
- Support Level
- GMAB $28.08
- ZTO $18.31
- Resistance Level
- GMAB $30.78
- ZTO $19.22
- Average True Range (ATR)
- GMAB 0.68
- ZTO 0.36
- MACD
- GMAB 0.10
- ZTO 0.02
- Stochastic Oscillator
- GMAB 84.63
- ZTO 64.75
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About ZTO ZTO Express (Cayman) Inc. each representing one ordinary share.
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 19.4% in 2024. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 78% voting rights as of March 31, 2025. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 8.9% interest.